DNER and breast carcinoma: There have been multiple pre-clinical studies in the evaluation of BET-inhibitors in TNBC with promising activity in growth inhibition in vitro and in vivo [77,78,79], in tamoxifen-resistant ER-positive breast cancer in vitro and in luminal B breast cancer mouse models [80,81].